What will be the medical insurance price of dasatinib in 2024? How much do patients actually need to pay after medical insurance reimbursement?

Dasatinib is a targeted drug used to treat chronic myelogenous leukemia (CML) and other types of leukemia. The drug has been launched in the country and has been included in the medical insurance system. Due to its remarkable efficacy, especially in patients with treatment-resistant and relapsed CML, dasatinib has become an important drug in the treatment of leukemia. However, the price of dasatinib is relatively high, so many patients need to pay attention to the actual payment after medical insurance reimbursement when purchasing.

According to the latest medical insurance price information, the price of the original drug of dasatinib is approximately several thousand yuan. The specific price will fluctuate depending on the specifications of the drug and the pharmacy, so patients need to consult the local hospital pharmacy for specific price information. After medical insurance reimburses the patient, the actual burden will be reduced, but the reimbursement ratio and final payment amount will vary according to different regions and medical insurance policies. For example, in some areas, medical insurance can reimburse 80%-90% of drugs, while in other areas, the reimbursement ratio may be lower.

Patients need to understand the actual payment after medical insurance reimbursement based on the specific policies of their region. If the patient's hospital or pharmacy cooperates with a medical insurance network, the reimbursed price will usually be much lower than the market price. The specific payment amount will be affected by factors such as the reimbursement ratio of medical insurance, whether the patient meets the reimbursement conditions, and the place where the drug is purchased. Therefore, it is recommended that patients consult the hospital pharmacy or medical insurance department before purchasing to understand accurate reimbursement information and actual payment costs.

Although the original drug of dasatinib is more expensive, patients can also consider purchasing some cheaper generic versions through overseas channels. For example, the generic version of dasatinib produced by Mylan in India is priced at about five to six hundred yuan, while the price of the generic version of natco in India is also similar. Through generic drugs, patients can reduce their financial burden without affecting the efficacy. However, when purchasing generic drugs, patients need to ensure that they are purchased through legal channels to ensure the quality and safety of the drugs.

Reference materials:https://go.drugbank.com/drugs/DB01254